We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Acarboseis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Acarbose studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2003–2016 with a typical study size of 1,429 participants.
Based on 4 studies · 2 RCTs · 1,429 total participants
Confidence
LowBy outcome
Acarbose has an evidence score of 4/10 — emerging evidence based on 4 indexed studies. An oral diabetes drug (alpha-glucosidase inhibitor) that blunts post-meal glucose spikes. It robustly extended lifespan in male mice in the NIA aging program and reduced cardiovascular events in human prevention trials. Human longevity benefit is unproven; the main downside is gas/GI side effects. A prescription drug taken off-label, not a supplement. Representative study: PMID 15164169.
The commonly studied dose of Acarbose is Off-label use mirrors diabetes dosing: taken with the first bite of carbohydrate-containing meals, titrated from a low dose (e.g. 25 mg) up to 50–100 mg per meal as GI tolerance allows. A prescription drug, not an approved longevity regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Last reviewed June 2026 · evidence from 4 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Acarbose (Precose, Glucobay)
An oral diabetes drug (alpha-glucosidase inhibitor) that blunts post-meal glucose spikes. It robustly extended lifespan in male mice in the NIA aging program and reduced cardiovascular events in human prevention trials. Human longevity benefit is unproven; the main downside is gas/GI side effects. A prescription drug taken off-label, not a supplement.
Acarbose robustly extended lifespan in male mice (NIA ITP) and reduced cardiovascular events and diabetes progression in human prevention trials, but no human study shows it extends lifespan, and GI side effects limit tolerability — so the longevity use is promising but unproven and off-label.
Acarbose is an alpha-glucosidase inhibitor that slows the breakdown of complex carbohydrates in the gut, blunting post-meal (postprandial) glucose and insulin spikes — in effect a partial 'carbohydrate blocker.' It is FDA-approved for type-2 diabetes.
Its geroscience credentials are strong for an oral drug: in the NIA Interventions Testing Program, acarbose robustly extended lifespan in genetically heterogeneous mice (most strikingly in males), one of the more reproducible pharmacological longevity results.
In humans, the STOP-NIDDM trial showed acarbose reduced progression to diabetes and lowered cardiovascular events and new hypertension in people with impaired glucose tolerance, and other trials/meta-analyses support a cardiovascular signal tied to flattening postprandial glucose.
The honest gap, as with the other geroprotectors, is that no human trial shows acarbose extends lifespan or healthspan. Its tolerability ceiling is gastrointestinal: undigested carbohydrate reaching the colon causes flatulence, bloating, and diarrhea, which is dose-limiting for many.
It is generally safe (it is not systemically absorbed much), inexpensive, and does not cause hypoglycemia on its own. Acarbose is a prescription drug used off-label for longevity/glucose-smoothing; it is not a dietary supplement.
The score reflects robust animal lifespan data and real human cardiovascular/glycemic benefit against unproven human longevity and GI tolerability limits.
Acarbose inhibits intestinal alpha-glucosidase enzymes, slowing complex-carbohydrate digestion and blunting the post-meal glucose and insulin surge.
Lower glucose/insulin excursions reduce glycemic variability — the proposed basis of both its cardiovascular and longevity effects.
Carbohydrate reaching the colon feeds fermentation, raising short-chain fatty acids — a proposed contributor to the lifespan effect (and the GI side effects).
How Acarbose works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label use mirrors diabetes dosing: taken with the first bite of carbohydrate-containing meals, titrated from a low dose (e.g. 25 mg) up to 50–100 mg per meal as GI tolerance allows. A prescription drug, not an approved longevity regimen.
Loading: Start low (25 mg with one meal) and titrate up slowly to limit gas/bloating; no loading dose.
Take with food
| Form | Type |
|---|---|
| 💊Oral tablet with meals | Recommended |
Inexpensive generic; no advantage to grey-market sourcing.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: With the first bite of carbohydrate-containing meals; no benefit on carb-free meals.
Dose-response data unavailable. The current published research for Acarbose does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Extended lifespan in male mice in the NIA aging program — not demonstrated in humans.
Reduced cardiovascular events and progression to diabetes in people with impaired glucose tolerance.
Flattens post-meal glucose spikes without causing hypoglycemia on its own.
Flatulence, bloating, and diarrhea from colonic carbohydrate fermentation — dose-limiting for many.
Avoid — increased colonic gas and osmotic load worsen symptoms.
Watch for hypoglycemia; treat with glucose, not table sugar.
Limited benefit — acarbose only acts on dietary carbohydrate.
Combination can cause hypoglycemia — treat with glucose (not sucrose), since acarbose blocks sucrose digestion.
May reduce acarbose's effect.
Tip: Start low and titrate; improves over weeks as the gut adapts.
Tip: Dose-related; reduce dose if troublesome.
Tip: Reversible; more likely at high doses — monitor on long-term high-dose use.
The best time to take Acarbose is with meals. Take it with food. Must be taken with the first bite of a carbohydrate-containing meal to inhibit carb digestion; ineffective without dietary carbohydrate.
Acarbose is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are flatulence / bloating, diarrhea / abdominal discomfort, elevated liver enzymes. Use caution if any of these apply to you: Inflammatory bowel disease / intestinal obstruction; Cirrhosis; Diabetic ketoacidosis.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.